Latest news with #EuropeanSociety
Yahoo
16-05-2025
- Business
- Yahoo
Agenus says expanded MSS mCRC cohort data to be presented at ESMO GI
Agenus (AGEN) announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab in patients with microsatellite stable metastatic colorectal cancer will be presented at the 2025 European Society for Medical Oncology Gastrointestinal Cancers Congress in Barcelona, Spain. A poster presentation will feature updated findings from an expanded cohort of 123 patients, incorporating additional participants and extended follow-up to further assess clinical activity of the combination, including durability of response and overall survival, the company noted. Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on AGEN: Disclaimer & DisclosureReport an Issue Biotech Alert: Searches spiking for these stocks today Agenus price target raised to $4 from $3 at Baird Agenus's Regulatory and Clinical Developments Prompt Neutral Stance Amid Uncertain FDA Pathway Agenus Inc. Reports Q1 2025 Progress and Financials Agenus Inc. Earnings Call: Optimism Amid Challenges Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
15-04-2025
- Health
- Forbes
New Breakthrough Antibiotic Can Treat Drug-Resistant 'Super Gonorrhoea'
For the first time in 30 years, researchers have discovered a promising new antibiotic treatment for gonorrhoea, a potentially important milestone in the fight against growing antibiotic resistance. Gonorrhoea is one of several sexually transmitted infections which is fast-gaining resistance to existing antibiotic treatments, making it hard to effectively treat patients with drug-resistant strains of Neisseria gonorrhoeae, the bacteria responsible for the infection. The infection was listed as a 'high' priority in the World Health Organization's Bacterial Priority Pathogens List, 2024. Between 600,000-700,000 cases of gonorrhoea are diagnosed in the U.S. each year according to the CDC. 'Gonorrhoea has developed resistance to nearly all the antibiotics used for its treatment,' according to the CDC website. 'We are currently down to one last recommended and effective class of antibiotics, cephalosporins, to treat this common infection. This is an urgent public health threat because gonorrhoea control in the United States largely relies on our ability to successfully treat the infection.' The newly developed treatment, called gepotidacin, may offer a much-needed alternative to standard gonorrhoea therapies, particularly in light of rising global resistance to existing drugs. Just a few weeks ago, gepotidacin was approved by the FDA for the treatment of urinary tract infections in women and children, following positive trial results. The findings, published in The Lancet and also presented at the 2025 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) conference in Vienna earlier this week, come from a phase 3 clinical trial involving over 600 patients across six countries including the U.K. and the U.S. Gepotidacin works by stopping bacterial DNA replication, essentially stopping the division and multiplication of bacteria. Researchers compared gepotidacin, taken orally, to the current standard treatment combination: an injection of ceftriaxone combined with an oral dose of azithromycin. The study concluded that gepotidacin was as effective as the existing treatment combination and importantly, worked against strains of Neisseria gonorrhoeae known to be resistant to the currently recommended treatment. The treatment was found to be safe with no significant side-effects and the authors of the study also note that gepotidacin is only taken orally and could remove the need for an injection, making the treatment more accessible for patients.
Yahoo
12-04-2025
- Health
- Yahoo
Having This Common Respiratory Condition Triples The Risk of Dying, Scientists Warn
In recent winters, doctors have warned of a potential 'tripledemic'—a surge of three major respiratory illnesses at once. One of them is respiratory syncytial virus (RSV), which typically causes mild, cold-like symptoms in healthy adults. While RSV is most often associated with infants—it's the leading cause of hospitalization in babies under six months—it also poses a serious risk to older adults. In fact, RSV can lead to severe complications like pneumonia and chronic respiratory disease in adults over 60, resulting in an estimated 100,000 and 150,000 hospitalizations annually. 🩺SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week💊 However, doctors may have actually underestimated just how dangerous RSV can be for older adults. New research presented at the 2025 European Society of Clinical Microbiology and Infectious Diseases Global conference shows adults with RSV are 2.7 times more likely to die within a year than people without an RSV infection. Related: Signs of RSV in Older Adults According to Immunologists Between 2011 and 2022, researchers examined medical data from 5,289 adults diagnosed with RSV. After comparing their health outcomes to 15,867 people of similar age and stature who were not infected with RSV after one year, they concluded the following. The most significant difference between the two groups was a much higher risk of death. Based on the findings, adults of any age older than 18 faced a 2.7 higher risk of dying within one year of infection compared to the general population. People with RSV infection had to deal with more severe health problems over all, with hospitalization rates being more than double those without RSV infection (58% vs 28%). They also demonstrated four times higher admission to the intensive care unit (5.3% vs 1.4%). The repeated RSV-related hospital visits and complications also resulted in hefty medical bills. Over the year, people with RSV infections spent nearly $23,000 in healthcare costs compared to the estimated $10,000 adults without RSV spent. Related: Who Actually Needs To Worry About RSV in the Coming Weeks In one year, people with RSV infection were 3.1 times more likely to experience complications from COPD, and 4.6 times more likely to have complications from asthma. 'Exacerbations of COPD and asthma were the most common adverse clinical outcomes. These pre-existing conditions are already challenging in themselves, and RSV-ARI exacerbates their severity," said Maria João Fonseca, Ph.D., an associate director of Global Real World Evidence and Health Outcomes, Vaccines for the pharmaceutical company GSK and the study's lead author. "Because of this, it's crucial that we pay closer attention to patients with these underlying conditions to prevent further, potentially life-threatening complications.' 'One of the most striking findings from this study was the prolonged and significant impact of RSV-ARI,' Fonseca explains. 'Even after the acute phase, patients continued to experience worse outcomes compared to the general population. This underscores just how serious and enduring the effects of RSV-ARI can be.' Related: As for how to protect yourself from RSV? Experts recommend getting vaccinated. (There are currently three FDA-approved RSV vaccines, including GSK's AREXY vaccine.) The Centers for Disease Control and Prevention currently recommends the RSV vaccine for anyone 75 and older. That said, anyone 60 or older who is considered high risk for complications is advised to get immunized as well. If you're unsure where you fall in terms of risk factors, ask your doctor or general practitioner. 'Vaccination has proven highly effective in preventing severe outcomes from RSV," said Stanislava Bratković, a medical advisor for Vaccines at GSK and one of the study's authors. "Given the significant burden of RSV-ARI highlighted by our study, prioritizing vaccination for vulnerable populations is essential to reduce both health complications and associated costs.' Up Next:About RSV. Centers for Disease Control and Prevention. RSV in Older Adults. Centers for Disease Control and Prevention. Clinical and economic burden of respiratory syncytial virus in adults with acute respiratory infections – a Danish nationwide cohort study. European Society of Clinical Microbiology and Infectious Diseases Global 2025. Maria João Fonseca, Ph.D., is an associate director of Global Real World Evidence and Health Outcomes, Vaccines for the pharmaceutical company GSK. Stanislava Bratković is a medical advisor for Vaccines at GSK.
